Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125656 | 1.00 | CYSLTR2 (0.36) | CYSLTR2CYSLTR1ALDH1A1L3MBTL1TP53 | |
| SCHEMBL4121153 | 0.97 | CYSLTR2 (0.34) | CYSLTR2CYSLTR1ALDH1A1L3MBTL1TP53 | |
| SCHEMBL4121158 | 0.97 | CYSLTR2 (0.34) | CYSLTR2CYSLTR1ALDH1A1L3MBTL1TP53 | |
| SCHEMBL4125679 | 0.97 | CYSLTR2 (0.34) | CYSLTR2CYSLTR1ALDH1A1L3MBTL1TP53 | |
| SCHEMBL4124828 | 0.85 | MGAM (0.33) | ALDH1A1BACE1KMT2AKDM4EMAPT | |
| SCHEMBL4124829 | 0.85 | MGAM (0.33) | ALDH1A1BACE1KMT2AKDM4EMAPT | |
| SCHEMBL4124833 | 0.85 | MGAM (0.33) | ALDH1A1BACE1KMT2AKDM4EMAPT | |
| SCHEMBL30642221 | 0.80 | ALDH1A1 (0.37) | ALDH1A1BACE1KMT2ATSHRKDM4E | |
| SCHEMBL4115577 | 0.80 | BACE1 (0.31) | BACE1 | |
| SCHEMBL4115573 | 0.80 | BACE1 (0.31) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | CYSLTR2 1121/4885CYSLTR1 742/4885ALDH1A1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.